BRISBANE

Hollywood Star ‘The Pink Cadillac’ Hits Auction Blocks

Retrieved on: 
Friday, April 26, 2024
Wine, Pink Cadillac, Investment, LIVE, Cadillac

BRISBANE, Australia, April 26, 2024 (GLOBE NEWSWIRE) -- Imagine cruising the streets in this stunning pink Cadillac, but not just any ordinary pink Cadillac. The official vehicle and one of the original stars from the big screen featured alongside Clint Eastwood and Bernadette Peters – ‘The Pink Cadillac’.

Key Points: 
  • BRISBANE, Australia, April 26, 2024 (GLOBE NEWSWIRE) -- Imagine cruising the streets in this stunning pink Cadillac, but not just any ordinary pink Cadillac.
  • The official vehicle and one of the original stars from the big screen featured alongside Clint Eastwood and Bernadette Peters – ‘The Pink Cadillac’.
  • This classic is a staple in many films and in rock and roll since Elvis cruised around in a pink Cadillac in the 1950s.
  • You can view images of The Pink Cadillac here.

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Retrieved on: 
Tuesday, April 23, 2024
Neuro-Oncology (journal), First grade, FDA, Society, University, BRAF V600, Day One, Hospital, Acne, Safety, Food, Biopharmaceutical, Conference call, Nausea, Insurance, Conference, Research, Webcast, Viral, Speech, Fatigue, Human, Disease, BRAF, Vomiting, Patient, Medicine, Headache, Event, Rash, Constipation, Diagnosis, Head, Neoplasm, Upper respiratory tract infection, PRS, Xeroderma, Fever, Caregiver, Ageing, Pharmaceutical industry

BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.

Key Points: 
  • With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.
  • “We are very proud that our first approved medicine addresses this serious and life-threatening disease of childhood and adolescence.
  • BRAF is the most commonly altered gene in pLGG, with up to 75 percent of children having a BRAF alteration.
  • “This is a tremendous moment not only for Day One, but also for the broader pediatric brain tumor community.

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, April 16, 2024
Employment

BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

Key Points: 
  • BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
  • The equity awards were approved on April 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • In the aggregate, the new non-executive employees received options to purchase 27,480 shares of Annexon common stock.
  • The options carries a ten-year term and an exercise price per share equal to $5.74, which was the closing price of Annexon’s common stock on April 15, 2024, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.

NOVONIX Announces Participation in April Investor Events

Retrieved on: 
Tuesday, April 9, 2024
USN, RET, Admiral, AGM, ASX, AEST, EDT, NVX

BRISBANE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX”), a leading battery materials and technology company, today announced that members of the executive team are scheduled to participate in the following upcoming investor events in April 2024:

Key Points: 
  • BRISBANE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX”), a leading battery materials and technology company, today announced that members of the executive team are scheduled to participate in the following upcoming investor events in April 2024:
    NOVONIX’s Annual General Meeting will be held in Brisbane, Australia on April 17th, details for participation can be found at the designated AGM webpage ;
    Dr. Chris Burns, CEO of NOVONIX, will provide prepared remarks in a business update webcast for the quarter-ended March 31st, 2024.
  • The webcast link and presentation materials will be available Wednesday, April 17th at 8:30 am AEST or Tuesday, April 16th at 6:30 pm EDT;
    Maxim Group is hosting their International Mining Collaboration: The World Needs More Mining & Processing virtual conference on April 23rd with NOVONIX participating at 11:30 am EDT; and
    Janney Montgomery Scott Virtual CEO Fireside Chat, April 24th at 1:00 pm EDT.
  • This announcement has been authorized for release by NOVONIX Chairman, Admiral Robert J. Natter, USN Ret.

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
HCC, Head, Growth, Immunotherapy, Patient, Tumor microenvironment, Cancer, Renal cell carcinoma, AACR, Bevacizumab, RCC, Neoplasm, Therapy, Nivolumab, ASCO, Tempest, Kidney cancer

These new data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022.

Key Points: 
  • These new data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022.
  • “Preclinical data presented at AACR further demonstrate that TPST-1120 has the potential to positively transform the tumor microenvironment and expand the activity of anti-tumor immunity in kidney cancer,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest.
  • In preclinical models of renal cell carcinoma (RCC), treatment with TPST-1120 reduced tumor growth by 52%-56% as monotherapy.
  • Additional improvement in anti-cancer activity was demonstrated in combination treatment with standard first-line RCC cabozantinib or anti-PD1 therapy, where tumor inhibition was 81% and 74%, respectively.

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Retrieved on: 
Thursday, April 4, 2024
HCC, Combination therapy, Nivolumab, Head, Patient, Bevacizumab, Therapy, Cancer, PD-1, Pharmaceutical industry

These earlier Phase 1 data complement the positive Phase 1b/2 data reported in October 2023 from a global randomized study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC, which showed clinical superiority of the TPST-1120 arm across multiple study endpoints and relevant biomarker-defined patient subpopulations.

Key Points: 
  • These earlier Phase 1 data complement the positive Phase 1b/2 data reported in October 2023 from a global randomized study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC, which showed clinical superiority of the TPST-1120 arm across multiple study endpoints and relevant biomarker-defined patient subpopulations.
  • “In this Phase 1 study of TPST-1120, we saw the first evidence of anti-tumor activity in multiple cancer types, affirming our belief that PPARα inhibition is an exciting and novel approach for cancer treatment,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest.
  • “These early-phase data are supported by the positive top line results of the ongoing randomized Phase 1b/2 trial in first-line HCC.
  • We believe there is tremendous potential for TPST-1120 to make a meaningful impact for patients and we look forward to providing updated data this year.”

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 3, 2024
Webcast, Eye, Brain, Conference

BRISBANE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 11:00 a.m.

Key Points: 
  • BRISBANE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 11:00 a.m.
  • ET.
  • A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com.
  • A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

NOVONIX Limited and Lithium Energy Limited to Combine Natural Graphite Interests with Intention to Take Combined Business Public

Retrieved on: 
Tuesday, April 2, 2024
Lithium, Corella, Mount, ASX, IPO, Mineral, Australian Securities Exchange, NVX, LEL

NOVONIX Limited (“NOVONIX”) and Lithium Energy Limited (“LEL”) to contribute their natural graphite exploration interests into a new company, Axon Graphite Limited (“Axon”)

Key Points: 
  • NOVONIX Limited (“NOVONIX”) and Lithium Energy Limited (“LEL”) to contribute their natural graphite exploration interests into a new company, Axon Graphite Limited (“Axon”)
    BRISBANE, Australia, April 03, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or “the Company”), a leading battery materials and technology company, today announced that it has signed a definitive agreement under which its wholly owned subsidiary, MD South Tenements Pty Ltd, which holds the Mount Dromedary natural graphite exploration interests, will be divested to Axon Graphite Limited (“Axon”), a subsidiary of Lithium Energy Limited (ASX: LEL).
  • LEL will contribute its interest in its Burke and Corella graphite projects to Axon pursuant to the agreement.
  • As consideration for the transaction, NOVONIX will receive shares in Axon, which the parties intend to list on the Australian Securities Exchange (“ASX”).
  • The shares held by each of NVX and LEL will likely be held in escrow for a period of 24 months.

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

Retrieved on: 
Tuesday, April 2, 2024
IgA nephropathy, Atacicept, Congress, Immunoglobulin A, Persistent, Therapy, Pharmaceutical industry

BRISBANE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced two presentations of data from the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be made at the 61st European Renal Association Congress (ERA24), which is taking place May 23—26, 2024, both virtually and in Stockholm.

Key Points: 
  • BRISBANE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced two presentations of data from the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be made at the 61st European Renal Association Congress (ERA24), which is taking place May 23—26, 2024, both virtually and in Stockholm.
  • Phase 2b ORIGIN Study Open Label Extension with Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria: Week 72 Interim Analysis

U.S. Government Selects NOVONIX to Receive US$103 Million in Qualifying Advanced Energy Project Tax Credits

Retrieved on: 
Monday, April 1, 2024
IRA, EV, USN, RET, Riverside, Recycling, Admiral, ASX, Sale, NVX, Internal Revenue Code, ESS, Inflation, Internal Revenue Service, Government, Average revenue per user

Importantly, under the IRA, a qualifying advanced energy project credit can be monetized through its sale for cash, in addition to using this tax credit to offset income tax liability.

Key Points: 
  • Importantly, under the IRA, a qualifying advanced energy project credit can be monetized through its sale for cash, in addition to using this tax credit to offset income tax liability.
  • The Company has a period of two years within which to satisfy the requirements and claim the tax credit.
  • This is the latest example of NOVONIX’s continued support from the U.S. government.
  • Dr. Chris Burns, CEO of NOVONIX, said, “In a period already filled with company milestones, the approval of our 48C application strengthens our financing strategy and demonstrates another significant landmark for NOVONIX.